US FDA approves Zevra's treatment for rare genetic disease
Adds details on disease in paragraph 4, FDA comment in paragraph 5, label warning in paragraph 8
Sept 20 (Reuters) -The U.S. Food and Drug Administration has approved Zevra Therapeutics' ZVRA.O drug for a rare and fatal genetic disorder, making it the first treatment to get a nod for the condition, the health regulator said on Friday.
The company has been trying for years to bring the drug to market after the FDA previously declined to approve it and extended a review of the treatment.
The oral drug, branded as Miplyffa, has now been approved for the treatment of Neimann-Pick disease type C - a rare genetic condition that affects the nervous system and other organs.
On average, people affected by this disease only live for about 13 years.
"The first-ever approval of a safe and effective drug option for NPC will undoubtedly support the essential medical needs of those suffering," said Janet Maynard, a director at the FDA's Center for Drug Evaluation and Research.
Miplyffa, in combination with miglustat, which is branded as Zavesca, has been cleared to treat neurological symptoms associated with NPC in adults and children 2 years of age and older.
The company did not immediately respond to a Reuters request for comment on pricing and availability.
Miplyffa comes with a warning for hypersensitivity reactions including hives and angioedema, a condition that causes swelling under the skin.
Zevra gained access to the drug through its acquisition of Orphazyme, the original developer, in 2022.
Shares of the company were halted pending news.
Reporting by Sriparna Roy and Kashish Tandon in Bengaluru; Editing by Devika Syamnath
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
